Navigation Links
Anti in Biological Technology

FDA Approves Ranexa(R) for First Line Anti Anginal Use and Adds New Claims for Reduction of Ventricular Arrhythmias, Bradycardia, New Atrial Fibrillation and HbA1c

... which is difficult to treat because some anti anginal medications such as beta blockers ... controlled or intolerant to first-line anti anginal therapies. CV Therapeutics has granted ... controlled or intolerant to first-line anti anginal therapies. CV Therapeutics also has other ...

Immureboost Inc Announces a Change of Name to Fountain Healthy Aging Inc

... half alone, and to US$70 Billion in the next 3 years. The worldwide global anti aging market is expected to reach US$115.5 Billion by 2010, and is now one ... industry sectors worldwide. We have a range of products targeted at the anti aging market, including our revolutionary flagship product Vitalife, which ...

Sanofi-aventis Announces Second Quarter 2009 Results

... 1. Results from the SEPIA-ACS1 TIMI 42 phase II trial, evaluating the efficacy and tolerance of otamixaban (an intravenous selective anti Xa factor) in patients with acute coronary syndrome (without ST segment elevation) will also be presented at a plenary session on August 30. ...

SIRO Group Appoints Scott L. Spector as President, Strategic Operations, for its European Business

... increasing responsibility over a 9-year period, serving as General Manager for their Paris, France office and Global Finance Director for the CNS and anti Infective business units. Mr. Spector played a key role in integrating newly acquired businesses, growing operations, implementing business ...

Preclinical Data From Amgen's Oncology Pipeline to be Presented at AACR

... pm) -- Involvement of the CSF-1/CSF-1R interaction in the control of angiogenesis Overview: Two different neutralizing rat anti murine CSF-1R monoclonal antibodies (mAb), M279 and AFS98 were evaluated for their effect on mouse corneal angiogenesis and corneal ...

CV Therapeutics' Board of Directors Rejects Astellas' Tender Offer

... as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line anti anginal therapies. CV Therapeutics also has other clinical and preclinical drug development candidates and programs. Additional Information ...

CV Therapeutics Advises Stockholders to Take No Action at This Time in Response to Astellas' Tender Offer

... as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line anti anginal therapies. CV Therapeutics also has other clinical and preclinical drug development candidates and programs. Additional Information ...

CV Therapeutics' Board of Directors Rejects Astellas Unsolicited Proposal

... as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line anti anginal therapies. CV Therapeutics also has other clinical and preclinical drug development candidates and programs. Except for the historical ...

CV Therapeutics Reports 2008 Fourth Quarter and Full Year Financial Results

... as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line anti anginal therapies. CV Therapeutics also has other clinical and preclinical drug development candidates and programs. Except for the historical ...

BioCryst Reports Fourth Quarter and Year End 2008 Financial Results and Provides Corporate Update

... also presented a poster at ASH entitled, "BCX-4208 (RO5092888), a Purine Nucleoside Phosphorylase (PNP) Inhibitor is a Novel, Potent Orally Active anti T- and B-Cell Agent." Findings presented in this poster support the evaluation of BCX-4208 in the treatment of not only T-cell mediated diseases, ...

CV Therapeutics Statement on Unsolicited Proposal From Astellas

... as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line anti anginal therapies. CV Therapeutics also has other clinical and preclinical drug development candidates and programs. Except for the historical ...

BioCryst to Present Three Posters During the 50th American Society of Hematology Annual Meeting and Exposition

... at ASH is as follows: BCX-4208 (RO5092888), a Purine Nucleoside Phosphorylase ( PNP ) Inhibitor is a Novel, Potent Orally Active anti T- and B-Cell Agent (Poster # 1547) Saturday, December 6, 2008, 5:30 p.m. - 7:30 p.m. Pacific Time; Hall A A Phase II Study of the ...

CV Therapeutics Reports 2008 Third Quarter Financial Results

... as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line anti anginal therapies. CV Therapeutics also has other clinical and preclinical drug development candidates and programs. Except for the historical ...

Savient's Pegloticase Data in Treatment-Failure Gout Patients Presented at 72nd Annual Meeting of the American College of Rheumatology Conference

... remained relatively constant during extended therapy with pegloticase. - Neutralizing antibodies and clinically relevant titers of anti pegloticase IgE were not present in any of the patients with continued use of pegloticase out to as long as 18 months. These ...

MedImmune Presents Data Highlighting its Progressive Inflammatory Disease Portfolio at the 72nd Annual Meeting of the American College of Rheumatology

... Carlesso, Ph.D., Tuesday, October 28 from 9:00 a.m. - 11:00 a.m. in Hall A, Abstract: 1843 -- In vitro properties of CAM-3001, a human anti GM-CSF receptor antibody for the treatment of patients with rheumatoid arthritis - Matthew Sleeman, Ph.D., Tuesday, October 28 from 9:00 ...

BioElectronics Corp Aggressively Expands Sales into Middle East

... demand for drug-free medical products," said Andrew J. Whelan, CEO of BioElectronics Corporation. "There is well established need for drug free anti inflammatory therapy in the Middle East which we expect to capture and expand." Whelan explained that Dr. Halawy has had significant sales ...

NIMOTUZUMAB CLINICAL DATA PRESENTED AT ASCO ANNUAL MEETING

... the use of nimotuzumab from the pediatric population to adults with high grade brain tumors. "Pharmacodynamic (PD) study of Nimotuzumab, an anti epidermal growth factor receptor (EGFR) monoclonal antibody (MAb), in patients with unresectable squamous cell carcinoma of the head and neck ...

ULURU Inc. to Present at the 8th World Biomaterials Congress

... be marketed throughout Europe and other international markets. The initial wound dressing containing an active agent, silver, an anti microbial and anti bacterial agent, has recently completed the necessary GLP toxicology studies and we expect to file for 510k approval with the FDA in the second half ...

Depth of MedImmune's Respiratory Disease Research Program Highlighted at Annual Meeting of the American Thoracic Society

... Controversies in Clinical Asthma (Poster Session: Safety Profile, Pharmacokinetics and Biologic Activity of a Single IV Dose of the anti IL-5 Receptor Alpha Antibody MEDI-563 in Patients with Mild Asthma, publication page A569)-Tuesday, May 20 from 8:15 a.m.- 11:00 a.m., Metro ...

Sidec Announces the First Protein Tomography(TM) Award at Sidec's Executive Forum at PEGS

... "During PEGS it became obvious that studying molecular mechanisms is indeed a crucial step in antibody development. Even for some of the best studied anti cancer drug targets, such as CD20, a fundamental understanding of the drug mechanisms is still lacking. Hence, Sidec's Protein Tomography(TM) Award ...

Medarex Announces Presentations at Annual Meeting of the American Association for Cancer Research

... Lung, Brain/CNS and Sarcoma Session) - Poster session scheduled for Wednesday, April 16, 2008 at 8:00 a.m. -- "Preclinical development of anti B7-H4 therapeutic antibodies" (Abstract #4986, Developmental Immunotherapy Session) - Oral presentation scheduled for Tuesday, April 15, 2008 ...

BioElectronics Announces Canadian Retail Product Launch

... This agreement will usher in a new era for biophysics medicine," said Andrew Whelan, President of BioElectronics. "ActiPatch is a unique drug free, anti inflammatory therapy, which will retail in Canada at market disruptive prices providing therapy for less than $1.50 per day. We are confident and ...

YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION

... is anticipated early in 2008. The poster presentation is entitled "Preliminary Results Of An Escalating Dose (Phase I /II Clinical) Trial Of The anti EGFR Monoclonal Antibody Nimotuzumab In Combination With External Radiotherapy In Patients Diagnosed With Stage IIB, III or IV NSCLC Unsuitable For ...

Detection of antibody-stained cell surface and intracellular protein targets with the Agilent 2100 bioanalyzer

... the cells were incubated with APC-labeled anti hCD4-antibody. After washing and ... They were then stained with anti GR antibodies and APC-conjugated ... Reagents anti hCD3 APC antibody, anti hCD4 APC antibody ...

Apoptosis detection by annexin V and active caspase-3 with the Agilent 2100 bioanalyzer

... with camptothecin or by incubation with anti Fas-antibodies. Different readouts were chosen ... cells were treated for two and four hours with anti Fas antibodies to induce apoptosis. In ... 5 x 105/ml with 1 M camptothecin or 0.5 g/ml anti Fas-antibody for 224 h to induce apoptosis. ...

Turbo Tax Online can teach new Web concepts a business lesson

... design flaws, I can't complain about the ease of use and the ease of mind that this product delivers in straight-forward fashion. TurboTax: The anti 2.0 By no modern definition is TurboTax Online a Web 2.0 product. In fact, some might even scoff that I'd take the time to write about an old ...

Quantitative Analysis of the Cell Cycle in Imaging Applications

... Buffer and stained simultaneously with Alexa Fluor 488 (Invitrogen, A-20000) conjugated anti-BrdU (Cat. No. 555627). Alexa Fluor 647 conjugated anti phospho-Histone H3 (Serine 28) (Cat. No. 558217), and Alexa Fluor 555 (Invitrogen A- 20009) conjugated anti-Ki-67 (Cat. No. 610969) in PBS with 3% ...

The use of CypHer5 for receptor internalization studies in both a range of GPCRs and a non-GPCR

... of CypHer5 Mono NHS Ester.

3. The final dye:protein (D:P) ratio for CypHer5 labelled anti-EGFR was calculated to be 1.4:1 (the CypHer5 anti VSV-G antibody uses a D:P ratio of between 1.5:1 and 3.0:1 for optimum performance).

4. Labelled antibody should immediately be diluted ...

Detection of mRNAs on Cryosections of the Cardiovascular System Using DIG-Labeled RNA Probes

... type VIII collagen) and immunohistochemical characterization of vascular cells using cell type-specific antibodies (smooth muscle cells: anti smooth muscle actin, Enzo; endothelial cells: von Willebrand factor, Sigma; macrophages: CD68, DAKO) and a peroxidase staining procedure ...
Other Contents
(Date:12/5/2014)... , Dec. 4, 2014  Tute Genomics, a leader ... million in Series A1 funding led by UK-based Eurovestech. ... participated in the investment round. "We are ... community adopts next-generation sequencing and seeks new approaches for ... Reid Robison , MD MBA, and CEO of Tute ...
(Date:12/3/2014)... 2014   Marvin Test Solutions , a ... for military, aerospace, and manufacturing organizations, today announced ... TS-900 PXI semiconductor test platform . The ... systems to customers at a fraction of the ... ATE. "Our semiconductor customers asked ...
(Date:11/21/2014)... November 18, 2014 According to ... by Systems (Video, RFID, Access Control, Intrusion Detection, Parking ... Banks, Government), Component Service Geography - Global Forecasts to ... is projected to be around $25 Billion in 2014 ... growing at a CAGR of 8.69%. Browse ...
Breaking Biology News(10 mins):Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3
(Date:12/20/2014)... Weddingshe.com has recently announced its new collection of sweet ... occasion dresses for the coming new year. , ... for global women. Now, all the models on its ... off. Among the new items, the model of 10986064 ... very popular. What’s more, Weddingshe.com also provides a fast ...
(Date:12/20/2014)... holidays can be anything but joyous for people with ... and other allergy triggers. "The dust from the ... away in dank basements or dusty attics is triggering ... Shah, an affiliate faculty member at Loyola University Chicago ... Shah, who is also an allergist at Gottlieb ...
(Date:12/20/2014)... Atore, Inc, (San Francisco, CA CEO: ... birthday focused portal on December 17th, 2014. , ... both US and Japan. , MERRY BIRTHDAY SITE : ... , MERRY BIRTHDAY MESSAGE is part of 5 ... , Features, Choose from thousands of stock photos to ...
(Date:12/20/2014)... The Twin Cities DI Day is ... the nation! Over 250 financial professionals come together each ... the industry, get motivated to protect their clients and ... and overcoming the challenges of disability. , On September ... came together to attend The 13th Annual Twin Cities ...
(Date:12/19/2014)... Sweetdressy.com , a leading wedding dress manufacturer for ... cheap prom dresses for ladies worldwide. The prom dresses ... clients can buy these dresses at the website of ... cuts and delicate craftsmanship, and most of them are ... shipping costs are available for all of their dresses. ...
Breaking Medicine News(10 mins):Health News:Tons of New-in Winter Sweet 16 Dresses from Weddingshe Online Now 2Health News:Holiday Trimmings Can Trigger Allergies 2Health News:Atore, Inc. Releasing the First Birthday Portal 2Health News:The 13th Annual Twin Cities DI Day Now On Video 2Health News:The 13th Annual Twin Cities DI Day Now On Video 3Health News:Cheap Prom Dresses Online Now at Sweetdressy.com 2
Other TagsOther Tags